Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK1278863 for Ischemic Protection in Aortic Aneurysm Repair
NCT01920594Phase 2Completed
- Sponsor
- GSK
- Start
- Oct 2013
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in ischemia-reperfusion injury (IRI) comparing GSK1278863 with Placebo (2 arms). Primary endpoints: Change From Baseline to Peak in Cerebrospinal Fluid (CSF) S100 Beta Within 48 Hours and Change From Baseline to Peak in CSF Glial Fibrillary Acidic Protein (GFAP) Within 48 Hours. Started Oct 2013; status: completed.
02
Drugs
daprodustat
03
Conditions
ischemia-reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT01920594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01920594.